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Abstract
Background: Epidermal growth factor (EGF) and its receptor (EGFR) constitute a principal growth-promoting pathway 
in endometrial cancer cells. Pre-clinical studies were undertaken to compare the expression of EGFR isoforms and the 
downstream effects of activating or blocking EGFR function in Ishikawa H cells, derived from a moderately 
differentiated type I endometrioid adenocarcinoma, or in Hec50co cells, derived from a poorly differentiated type II 
adenocarcinoma with papillary serous sub-differentiation.
Results: We investigated whether EGFR mutations are present in the tyrosine kinase domain (exons 18-22) of EGFR and 
also whether EGFR isoforms are expressed in the Ishikawa H or Hec50co cell lines. Sequence of the EGFR tyrosine kinase 
domain proved to be wild type in both cell lines. While both cell lines expressed full-length EGFR (isoform A), EGFR and 
sEGFR (isoform D) were expressed at significantly lower levels in Hec50co cells compared to Ishikawa H cells. Analysis of 
gene expression following EGF vs. gefitinib treatment (a small molecule EGFR tyrosine kinase inhibitor) was performed. 
Early growth response 1, sphingosine kinase 2, dual specificity phosphatase 6, and glucocorticoid receptor DNA 
binding factor 1 are members of a cluster of genes downstream of EGFR that are differentially regulated by treatment 
with EGF compared to gefitinib in Ishikawa H cells, but not in Hec50co cells.
Conclusions: Type I Ishikawa H and type II Hec50co endometrial carcinoma cells both express EGFR and sEGFR, but 
differ markedly in their responsiveness to the EGFR inhibitor gefitinib. This difference is paralleled by differences in the 
expression of sEGFR and EGFR, as well as in their transcriptional response following treatment with either EGF or 
gefitinib. The small cluster of differently regulated genes reported here in these type I vs. type II endometrial cancer-
derived cell lines may identify candidate biomarkers useful for predicting sensitivity to EGFR blockade.
Background
Endometrial carcinoma is the most common gynecologic
malignancy in American women [1-3]. Type I endome-
trial cancers are generally of endometrioid subtype, well
differentiated, express estrogen and progesterone recep-
tors (ER and PR), and develop in a setting of estrogen
excess unopposed by the differentiating effects of proges-
terone [4,5]. Ishikawa H, a cell line derived from a moder-
ately differentiated endometrioid type I adenocarcinoma
[6], is hormone receptor positive and forms rudimentary
glandular structures in culture [7,8]. In contrast, type II
endometrial cancers include clear cell, serous, and poorly
differentiated endometrioid subtypes, are poorly differ-
entiated and result in more aggressive lesions [4,5]. Type
II tumors are typically resistant to hormonal growth reg-
ulation because they express less ER and PR. Hec50co
cells were derived from a metastatic type II endometrial
cancer and sub-differentiate into a serous subtype in
xenografted animal models [9]. Hec50co cells are poorly
differentiated in culture and do not express appreciable
levels of ER or PR [6].
No effective treatment is available for persistent or
recurrent endometrial cancer. New therapies using the
rationale that cancer cells express or amplify certain sig-
naling proteins, such as the epidermal growth factor
receptor (EGFR) family of tyrosine kinase receptors, are
under investigation, as described below.
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EGFR is the prototypic member of the ErbB/HER
receptor tyrosine kinase family and binds to multiple
ligands including EGF, transforming growth factor alpha,
and amphiregulin. EGFR plays a crucial role in cellular
functions implicated in cancer development [10], and has
been shown to be expressed in a large percentage of
endometrial tumors [11]. We previously investigated the
expression of EGFR and identified its downstream signal-
ing cascades in both Ishikawa H and Hec50co cells [12].
Tyrosine kinase inhibitors block EGFR autophosphoryla-
tion in both cell lines in vitro [12]. However, the well-dif-
ferentiated Ishikawa H cell line responds more robustly to
EGFR activation and is more sensitive to receptor inhibi-
tion compared to Hec50co cells, which are relatively
resistant. Specifically, fewer signaling intermediates are
activated or blocked downstream of EGFR in Hec50co
cells compared to Ishikawa H cells [12]. Also, cell cycle
regulatory events in response to the EGFR tyrosine kinase
inhibitor gefitinib are blunted in Hec50co cells compared
to Ishikawa H cells [13]. The reason these poorly differen-
tiated cells do not respond as well to inhibition of EGFR
activity is an interesting question that may have bearing
on resistance to tyrosine kinase inhibitors in the clinical
setting.
Human EGFR is encoded by two transcripts of 10.5 kb
and 5.8 kb (isoform A) both of which arise from a single
promoter region/gene on chromosome 7 [14]; the protein
product arising from these two transcripts is identical. In
addition to these two transcripts which encode the full-
length EGFR isoform, three alternative transcripts of 1.8,
2.4, and 3.0 kb, also are derived from the EGFR gene and
encode isoforms C, B, and D, respectively [15,16]. While
the 1.8 kb transcript results from read-through of an exon
(10) intron boundary, the 2.4 and 3.0 kb transcripts,
encoding isoforms B and D transcripts diverge from full-
length EGFR by incorporating alternate exons 15A or
15B. Exon 15A encodes a unique carboxy-terminal ser-
ine; exon 15B encodes an alternative 78-amino acid C-
terminal sequence (isoform D). Both of these alternately
spliced transcripts also encode alternative stop codons as
well as unique 3' untranslated regions (UTR) including
consensus polyadenylation sites (see Figure 1). While the
2.4 kb isoform B and its protein product have not been
well studied, the 3.0 kb isoform D transcript encodes a
90/110 kDa EGFR isoform that is associated with the cell
membrane through an unidentified mechanism [17] and
also can be detected in human serum [18,19]. These solu-
ble receptor isoforms resemble the avian secreted sEGFR
isoform, which has been shown to bind to ligand and to
inhibit ligand-dependent, anchorage-independent
growth of primary fibroblasts [15,20]. sEGFR/sHER
receptors also have been reported to modulate EGFR/
HER tyrosine kinase activity [21,22]. The 1.8 kb isoform
C transcript codes for a secreted 60/80 kDa soluble EGFR
protein that contains only subdomains I, II, and half of
subdomain III of the EGFR extracellular region followed
by a unique carboxy-terminal Leu-Ser and 3' UTR (Figure
1).
The tyrosine kinase inhibitor gefitinib (Iressa, ZD1839)
binds to the ATP binding site of the EGFR kinase domain
with a higher affinity than does ATP itself [23]. Heterozy-
gous somatic mutations of the EGFR tyrosine kinase
domain (exons 18-21) have been correlated with a posi-
tive response to gefitinib [24,25]. These missense (G719S/
C and L858R) and deletion mutations (in the region span-
ning codons 746-759) are located in exons 18 through 21
of EGFR and appear to confer tumor susceptibility to
gefitinib [24,25]. It has been hypothesized that such
mutations stabilize the interaction of EGFR with ATP or
gefitinib thereby resulting in an increase in both ligand
activation and inhibitor de-activation [24]. These muta-
tions are distinct from the variant EGFRvIII, discovered
in glioma and metastatic breast cancer, where mutant
receptors maintain constitutively active, ligand-indepen-
dent receptor activity; moreover, these latter extracellular
domain EGFR mutants do not interfere with the ability of
the receptor tyrosine kinase domain to bind to gefitinib
[24].
Here, we have sequenced the tyrosine kinase domain
(exon 18-22) of EGFR and also have determined the
expression of these EGFR isoforms in the two endome-
trial carcinoma cell lines described above. In addition, we
have evaluated the effects of gefitinib or EGF on gene
expression to better understand how these two cell lines
respond to treatment. We hypothesized that Ishikawa H
cells, previously found to be more responsive to EGFR
modulation with respect to signaling and cell cycle inhi-
bition, would express functional EGFR and show a robust
transcriptional response to EGF [12,13]. By contrast, we
hypothesized that Hec50co cells, previously found to be
more resistant to EGFR modulation with respect to sig-
naling [12] and cell cycle inhibition [13], might differen-
tially express EGFR or its related isoforms, and that these
expression patterns may predict a blunted transcriptional
response to EGF as well as to gefitinib. The results of
these pre-clinical studies contribute to our understanding
of the distinguishing cellular characteristics that control
drug performance in two well-characterized models of
endometrial cancer.
Methods
Drugs and chemicals
EGF was purchased from Invitrogen (Carlsbad, CA).
Gefitinib (Iressa, ZD1839) was provided by AstraZeneca
(Wilmington, DE and Cheshire, UK). The drug was dis-
solved in dimethyl sulfoxide (DMSO) for all in vitro stud-
ies.Albitar et al. Molecular Cancer 2010, 9:166
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Cells and culture conditions
Ishikawa H and Hec50co cells were provided by Dr. E.
Gurpide, New York University, and were cultured in
DMEM media (Sigma-Aldrich Inc., St. Louis, MO) sup-
plemented with 10% fetal bovine serum substitute (Fetal-
Plex, Gemini Bio-Products, Woodland, CA), 2 mM L-
Glutamine and 1× antibiotic-antimycotic solution
(GIBCO, Grand Island, NY). Cells were incubated either
with 0.1% DMSO (vehicle), 1 μM of gefitinib, or with 30
ng/ml EGF for 12 and 24 h before harvesting for gene
array or immunoblot studies as described below.
RNA isolation and microarray hybridization
Ishikawa H and Hec50co cells were cultured and treated
as described above. Cells were harvested by scraping, and
the pellets were washed twice with phosphate buffered
saline (PBS). Total RNA was prepared from the cell pel-
lets according to the manufacturer's protocol using
RNeasy spin columns (Qiagen Corp, Valencia, CA). RNA
quality was checked using the Agilent 2100 Bioanalyzer
(Agilent Technologies, Foster City, CA). All microarray
procedures were performed using the human Affyme-
trix™ HG-U133 plus 2.0 chips (Santa Clara, CA). Proce-
dures for the chip preparation and cDNA/cRNA
synthesis were performed according to instructions from
the manufacturer's manual, version 701025 Rev.5. Briefly,
5 μg of total RNA was used to generate double-stranded
cDNA using an oligo dT-primer containing the T7 RNA
polymerase promoter site and the One-Cycle Target
Labeling Kit. cDNA was purified via column purification
using the GeneChip Sample Cleanup Module, and bioti-
nylated cRNA was synthesized by in vitro transcription
using the GeneChip IVT Labeling kit. Biotin labeled
cRNA was purified (GeneChip Sample Cleanup Module),
and the absorbance was measured at 260 nm to deter-
mine yield (Nanodrop spectrophotometer). Twenty μg of
the labeled cRNA was fragmented; the quality of the puri-
fied cRNA and the fragmented cRNA was assessed using
the Agilent 2100 Bioanalyzer and the RNA 6000 Nano
LabChip kit. The labeled fragmented cRNA was hybrid-
Figure 1 Schematic Figure of Major Domains of EGFR Isoforms. Domains, exons and amino acid numbers of wt-EGFR (accession# NM_005228). 
EGFR isoform B arises from a transcript containing exon 15 and an alternate exon (15A) after exon 15, incorporating a Ser and a stop codon (accession# 
NM_201282). EGFR isoform C (accession# NM_201283) is a 60/80 kDa protein (p60) and arises from a readthrough of the boundary between exon 10 
and intron 10-11, incorporating 2 unique carboxy-terminal amino acids (Leu-Ser) and a stop codon. EGFR isoform D (accession# NM_201284) is a 90/
110 kDa protein (p110/sEGFR) and arises from incorporation of an alternate exon (15B) after exon 15, incorporating 78 unique amino acids and a stop 
codon.Albitar et al. Molecular Cancer 2010, 9:166
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ized to Affymetrix GeneChipHGU133 Plus 2.0 arrays for
16 h at 45°C following the Affymetrix protocol specific to
this array type. The washing and staining steps were per-
formed on the Affymetrix 450 fluidics station according
to the antibody amplification protocol (Fluidics script:
EukGE-WS2v5). The GeneChips were scanned using the
Affymetrix GeneChip Scanner 3000 (a wide-field, epiflu-
orescent near-confocal microscope with a patented flying
objective).
Real time PCR (qPCR)
Synthesis of cDNA from total RNA was performed using
the High-Capacity cDNA Archive Kit from Applied Bio-
systems, part number 4322171 (Foster City, CA). One mg
of total RNA was converted to cDNA in a μ1 ml 10×
Reverse Transcription Buffer, 0.4 μl 25× dNTPs, μ1.0 ml
10× random primers, 0.5 μl MultiScribe™ reverse tran-
scriptase, 50 U/μl and 7.1 ml nuclease-free water. The
reactions were incubated for 10 min at 25°C followed by
120 min at 37°C. Singleplex real time PCR was performed
in 384 well format using the Applied Biosystems 7900 HT.
Reactions were prepared in 10 ml volumes containing 10
ng cDNA, 0.5 ml of the 20× Target Assay Mix or endoge-
n o us  c o n t r o l ,  a n d  5 . 0  μ l  2 ×  T a q M a n  U n i v e r s a l  M as t e r
Mix. Relative quantification was obtained using the Com-
parative Ct method. This involves comparing the Ct val-
ues of the samples of interest with a control or calibrator
such as a non-treated sample or RNA from normal tissue.
We used untreated samples as calibrators. The Ct values
of both the calibrator and the samples of interest were
normalized to an appropriate endogenous housekeeping
gene (18S).
Reverse transcriptase polymerase chain reaction (RT-PCR)
First strand synthesis was performed according to the
instructions provided by Invitrogen™ Life Technologies
(Carlsbad, CA). For these studies, 1.0 μg of total RNA was
used to generate single-stranded cDNA via first strand
synthesis using SuperScript™ III in the presence of oligo-
(dT)20 primer and dNTP's. The mixture was heated to
65°C for 5 min and placed on ice for at least 1 min. First
Strand Buffer, dithiothreitol and SuperScript III were
added per the protocol directions and incubated for 1 h at
55°C followed by inactivation by heating at 70°C for 15
min. PCR was performed according to the instructions
provided by Qiagen, Inc (Valencia, CA) for their HotStar-
Taq Master Mix product. A total of 100 ng of cDNA was
added to the reaction as a template along with the appro-
priate primers and the PCR master mix. An annealing
temperature of 59°C was used, and PCR was performed
over 35 cycles. Equal amounts of the products were sepa-
rated by agarose gel electrophoresis, and a size marker
was included for molecular weight determination.
Immunoblot analysis of EGFR isoforms
Near-confluent cultures of Ishikawa H and Hec50co cells
were rinsed 3× with ice-cold PBS and harvested by scrap-
ing. Cells were solubilized with boiling SDS-lysis solution
(2.5% SDS, 0.5% NP-40, 0.5% deoxycholate) for five min-
utes. Following solubilization, lysates were diluted 1:9
with 50 mM Tris-HCl, pH 7.4, 190 mM NaCl, 6 mM
EDTA, 2.5% Triton X-100, and protease inhibitors (2 mM
PMSF, 1 mg/ml aprotinin, pepstatin, and leupeptin). Cell
lysate protein concentration was quantitated by Bio-Rad
DC assay.
CHO/EGFR and CHO/sEGFR [26] lysates were used as
positive controls for EGFR and sEGFR expression,
respectively. Samples were loaded onto 7.5% acrylamide,
1.5 mm-thick Hoeffer slab gels and electrophoresed for 4
hours at 30 mA (along with Bio-Rad Precision Plus MW
markers), followed by transfer to PVDF membrane by
semi-dry electroblotting (418 mA for 30 min). The mem-
brane was blocked for one hour with 5% non-fat dry milk
in 10 mM Tris-HCl, pH 7.4, 150 mM NaCl (TBS), and
rinsed 6× for 5 min with wash buffer (TBS plus 0.1%
Tween-20). The membrane was then successively probed
with antibody directed against β-tubulin (Cell Signaling
Technology, Danvers, MA, 1:500) and EGFR (sc-03, Santa
Cruz Biotechnology, Santa Cruz, CA, 1:500) or sEGFR
(1:4000) [26] in TBS plus 0.1% bovine serum albumin
(BSA) overnight, followed by 6× rinses with wash buffer
for 10 min each. The sEGFR-specific antibody is directed
against the unique carboxy-terminal sequence of the 3.0
kb sEGFR gene product [27], whereas the sc-03 anti-
EGFR antibody is directed against the EGFR intracellular
domain. Membranes were then incubated with secondary
antibody (goat anti-rabbit, 1:4000, Pierce) in TBS with
0.1% BSA for one hour followed by 6× rinses with wash
buffer for 10 min each. Immune complexes were detected
by enhanced chemiluminescence (Supersignal West
Femto, Pierce).
Sequencing exons 18-22 of EGFR
cDNA was generated as described above using primers to
query each EGFR subdomain (Figure 2). PCR was per-
formed to generate templates for sequencing (standard
PCR protocol, Tm of 59°C). Samples were sequenced at
the DNA Research Services Core Laboratory of the Uni-
versity of New Mexico (UNM) using an ABI 377 genetic
analyzer, capillary electrophoresis and ABI big dye termi-
nator ready reaction kits (Applied Biosystems, Carlsbad,
CA). The automated instrument system performs elec-
trophoretic separation and spectral detection of dye-
labeled DNA fragments to determine base sequence,
fragment size, or relative quantity. Sequencing reactions
are performed with fluorescent labels: four different dyes
identify the A, C, G, and T extension reactions. PrimersAlbitar et al. Molecular Cancer 2010, 9:166
http://www.molecular-cancer.com/content/9/1/166
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used for sequencing EGFR (exon 18-22) are presented in
Table 1.
Analytical approaches and data interpretation
We analyzed the effects of EGF and gefitinib on gene
expression in Ishikawa H and Hec50co cells at 12 h and
24 h normalized against specific controls. Two separate
experiments were run for each cell line, treatment, and
time point. Silicon Genetics' GeneSpring version 7.2
(Palo Alto, CA) was used to filter data using a fluores-
cent-threshold cutoff and a 2-fold differential cutoff. Two
different normalizations were employed: median-nor-
malization and normalization to specific samples,
depending on the comparisons being examined. Data
from the two cell lines, Ishikawa H and Hec50co, were
further compared using Venn diagrams. In addition, we
employed Ingenuity™ software (Redwood City, CA) to
generate common networks between linked genes with
analytical changes of 2-fold or more [28].
Results
EGFR sequencing in Ishikawa H and Hec50co cells
Exons 18-22 of the tyrosine domain of EGFR of Ishikawa
H and Hec50co cells were sequenced (Figure 3). PCR
products were detected on a DNA agarose gel (Figure 3A)
and were found to be the expected size (540 bp). No
mutations in the tyrosine kinase domain of EGFR (exons
18-22) were observed in either cell line at the amino acid
level. Two conservative single nucleotide polymorphisms
were identified that did not change the amino acid
sequence (data not shown); therefore, we conclude that
the EGFR tyrosine kinase domains are wild type in both
cell lines.
EGFR isoforms in Ishikawa H and Hec50co cells
Detection of EGFR isoforms in Ishikawa H and Hec50co
cells was conducted initially by RT-PCR. We designed
multiple primer sets specific for the EGFR extracellular
and intracellular domains (Figure 2). In addition, primers
that span regions of the internally-deleted variant and the
soluble isoforms were included (Table 1; see Materials
and Methods). The products of these reactions (Figure
3B) were expected to identify the expression of EGFR
wild type and soluble isoforms (Figure 1) as well as
EGFRvIII. PCR products were analyzed by agarose gel
electrophoresis to confirm size and abundance, using
primer templates as negative controls (Figure 3B). As
determined from the primer set locations and band sizes
on agarose gels, EGFRvIII expression was not detected.
Using semi-quantitative methods, we also detected the
message for the 1.8 kb sEGFR isoform (isoform C) at
comparable levels in both Ishikawa H and Hec50co cells
(Figure 3B). By these same methods the 3.0 kb sEGFR
transcript (isoform D, Figure 3B) appeared to be
expressed at higher levels in the Hec50co cells relative to
the Ishikawa H cells (isoform D transcript is just detect-
able in Ishikawa cells). The 2.4 kb isoform (B) was not
o b s e r v e d  i n  e i t h e r  c e l l  l i n e .  H o w e v e r ,  R T - P C R  i s  n o t
quantitative, and when immunoblot analysis was per-
formed to assess isoform D protein expression (Figure 4),
Figure 2 Schematic Figure of Wild Type EGFR Domains and Subdomains. This figure shows the number of exons, amino acids, and nucleotides 
in each domain. Arrows correspond to selected primers used to identify wild type EGFR and EGFR isoforms. Numbers below the arrows match the 
location of the primers on EGFR RNA sequence (accession#NM_005228). Names between arrow pairs correspond to the name of the primer set; Xcell 
and Intracell specify sequences encoding the extracellular and intracellular domains of EGFR (see Table 1).Albitar et al. Molecular Cancer 2010, 9:166
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more sEGFR protein was detected in Ishikawa H cells
using an antibody specific for the unique carboxy-termi-
nal sequence of isoform D [26] than was detected in
Hec50co cells. Both cell lines expressed wild type EGFR
with higher levels in Ishikawa H cells (Figure 4).
Effects of EGF and gefitinib on gene expression in Ishikawa 
H cells
Ishikawa H cells were incubated with either 30 ng/ml
EGF or 1 μM gefitinib for 12 and 24 h. Cells were har-
vested, and total RNA was isolated for microarray studies
using human Affymetrix™ HG-U133 plus 2.0 chips. The
expression of 134 and 150 genes was altered 2-fold or
more at 12 and 24 h, respectively, after exposure to EGF.
Forty-four genes were regulated both at the 12 and 24 h
time points (Additional File 1, Table S1). The expression
of 132 and 61 genes was altered at 12 and 24 h, respec-
tively, after gefitinib treatment. Twenty-five genes were
found to be regulated at both the 12 and 24 h time points
(Additional File 1, Table S1). While most genes were
induced or down-regulated similarly at 12 and 24 h, some
genes were differentially regulated. For example, the
expression of Splicing Factor 4 (SF4) was decreased by
0.472 fold at 12 h and increased by 3.639 fold at 24 h in
response to EGF in Ishikawa H cells. Sphingosine kinase 2
(SphK2) and protein inhibitor of activated STAT (PIASy)
showed a similar pattern in response to gefitinib:
decreased at 12 h but increased at 24 h. For those genes
regulated by both EGF and gefitinib, the majority demon-
strated an induction by one treatment and a down-regu-
Table 1: Primer Sets for Amplification of EGFR Isoforms and Mutants.
Primer set name Sequence Expected band size (bp)
EGFR forward extracellular 1 (Xcell 1) ccagtattgatcgggagagc 1873
EGFR reverse extracellular 1 (Xcell 1) acaacaccctggtctggaag
EGFR forward extracellular 2 (Xcell 2) agcctccagaggatgttcaa 1318
EGFR reverse extracellular 2 (Xcell 2) tggttttctgaccggaggt
EGFR forward extracellular 3 (Xcell 3) caaaaactgcacctccatca 854
EGFR reverse extracellular 3 (Xcell 3) ggatcttaggccccattcgtt
EGFR forward intracellular (Intracell) cctaagatcccgtccatcg 1769
EGFR reverse intracellular (Intracell) ttggtcctgggtatcgaaag
EGFR isoform B forward aacaacaccctggtctggaa 160
EGFR isoform B reverse tgaagcaaagggagaaattga
EGFR isoform C forward ggatattctgaaaaccgtaaaggaaa 96
EGFR isoform C reverse cgaaaagttctctctaaaacactgatt
EGFR isoform D forward ccagtgtgcccactacattg 221
EGFR isoform D reverse cgctgccatcattactttga
Sequencing primers (exon 18-22) forward ccaaccaagctctcttgagg 540
Sequencing primers (exon 18-22) reverse tgataggcactttgcctcctAlbitar et al. Molecular Cancer 2010, 9:166
http://www.molecular-cancer.com/content/9/1/166
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Figure 3 RT-PCR Agarose Gel of EGFR cDNA in Ishikawa H and Hec50co Cells. A) Band corresponds to EGFR exons 18-22, 540 bp in size, in 
Hec50co and Ishikawa H cells. B) Bands correspond to extracellular and intracellular domains of EGFR well as sEGFR isoforms B, C, and D.Albitar et al. Molecular Cancer 2010, 9:166
http://www.molecular-cancer.com/content/9/1/166
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lation by the other, indicating that activation and
b l o c k a d e  o f  E G F R  r e s u l t e d  i n  p r e d i c t a b l y  o p p o s i n g
effects on gene expression (Additional File 1, Table S1).
For example, early growth response 1 (EGR1), epithelial
membrane protein 1, FOS-like antigen 1, dual specificity
phosphatase 6 (DUSP6), plasminogen activator, uroki-
nase, sprouty homolog 2, sprouty homolog 4, and potas-
sium voltage-gated channel, Isk-related family member 3
(KCNE3) were all induced by EGF and down-regulated by
gefitinib at 12 h. Epithelial membrane protein 1, DUSP6,
EGR1, sprouty homolog 2, sciellin, 5'-nucleotidases, ecto
(CD73), and KCNE3 were all induced by EGF and down-
regulated by gefitinib at 24 h.
Effects of EGF and gefitinib on gene expression in Hec50co 
cells
Hec50co cells were incubated with either 30 ng/ml EGF
or 1 μM gefitinib for 12 and 24 h. Cells were harvested,
and total RNA was isolated as above. After excluding the
hypothetical gene products and the ESTs, the expression
of 35 and 58 genes was altered in response to EGF at 12
and 24 h compared to untreated control cells. Three
genes (fibroblast growth factor receptor 2, stanniocalcin
1, and kinesin family member 26A) were found to be reg-
ulated at both the 12 and 24 h time points in response to
EGF. The expression of 14 and 59 genes was altered in
response to gefitinib after 12 and 24 h, respectively, in
comparison to untreated controls. One gene, calcium
homeostasis endoplasmic reticulum protein, was found
to be regulated at both 12 and 24 h (Additional File 1,
Table S1).
Effects of EGF and gefitinib on gene expression in Ishikawa 
H vs. Hec50co cells
Gene expression in response to EGF and gefitinib was
further analyzed to determine commonly regulated
genes. Two genes, EGR1 (up-regulated) and polycystic
kidney disease 1-like (down-regulated), were commonly
regulated in both Ishikawa H and Hec50co cells in
response to EGF at 12 h (Additional File 1, Table S1).
Three down-regulated genes (papilin-proteoglycan-like
sulfated glycoprotein, fibroblast growth factor receptor 2,
and cadherin 16, KSP-cadherin) were similarly regulated
in both cell lines in response to EGF at 24 h. One gene,
glucocorticoid receptor DNA binding factor (GRLF1),
was found to be differentially controlled by gefitinib
(down-regulated in Ishikawa H and up-regulated in
Hec50co cells) at 12 h. SphK2 and PIASy were two com-
mon genes (both induced) in Ishikawa H and Hec50co
cells after 24 h of gefitinib treatment based on these gene
array data.
Real time PCR confirms changes in gene expression for 
selected genes
Findings from the array experiments were confirmed for
four genes by qPCR in Ishikawa H cells (Figure 5) and
Hec50co cells (Figure 6). These four transcripts were cho-
sen from diverse functional categories. We were inter-
ested in common genes between Ishikawa H and
Hec50co cells that would comprise a core set of tran-
scripts downstream of EGF/EGFR. We identified two
genes in this category for confirmation: EGR1, that was
induced by EGF at 12 h (3.365 fold in Ishikawa H and
2.442 fold in Hec50co cells); and glucocorticoid receptor
DNA binding factor 1 (GRLF1), that was down-regulated
by gefitinib at 12 h in Ishikawa H cells (0.483 fold) and
induced in Hec50co cells (2.73 fold). In addition, SphK2
was of special interest because it was differentially
Figure 4 Immunoblot Analysis of EGFR Isoform Expression in 
Ishikawa H and Hec50co Cells. Cell lysates from endometrial or trans-
fected control (CHO-EGFR, CHO-sEGFR) cell lines were resolved by 
SDS-PAGE (7.5% acrylamide), and immunoblotted using enhanced 
chemiluminescence with antibodies specific for either: A) EGFR (iso-
form A, p170, intracellular domain), or B) sEGFR (isoform D, p90/110). 
Anti-tubulin labelling is included as a loading control (lower panel, 
Figs. A and B). Molecular weight markers migrate at the positions indi-
cated: 250 kD, 150 kD, and 100 kD.Albitar et al. Molecular Cancer 2010, 9:166
http://www.molecular-cancer.com/content/9/1/166
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expressed in response to gefitinib over time in Ishikawa H
cells (down-regulated at 12 h and induced at 24 h).
DUSP6 is also a gene downstream of EGFR signaling
pathways. DUSP6 was induced by EGF and down-regu-
lated by gefitinib treatment at 12 h and 24 h in Ishikawa H
cells (Additional File 1, Table S1).
Gene networks
Analyzing the Affymetrix expression array data using
Venn diagrams and Ingenuity™ networks provided addi-
tional insight into the transcriptional response of
Ishikawa H and Hec50co cells to EGF and gefitinib.
Ishikawa H cells are clearly more responsive to gefitinib,
but Hec50co cells demonstrate similarities as well as
interesting differences, including the induction of a group
of pro-proliferative and compensatory factors at 24 h.
Such factors may be markers of resistance to gefitinib
worthy of future validation. These data are provided in
the Additional Files of this manuscript and discussed
below.
Discussion
To evaluate the potential therapeutic effects of tyrosine
kinase inhibitors in the treatment of endometrial cancer,
we previously have characterized the EGFR pathway in
endometrial cancer cells at the signaling level [12], with
respect to cell cycle [13], and now at the genomic level.
First we sequenced the tyrosine kinase domain of EGFR
(exon 18-22) and identified the isoforms present in
Ishikawa H cells (moderately differentiated) and Hec50co
cells (poorly differentiated). In both cell types, no muta-
tions were detected in EGFR that modify the amino acid
sequence in the ATP binding pocket. Transcripts encod-
ing the alternate EGFR isoforms, C and D, were detected
in both cell lines. Immunoblot analysis with an antibody
specific for sEGFR isoform D demonstrated that Ishikawa
Figure 6 Real Time PCR Graphs for Chosen Genes in Hec50co 
Cells. from qPCR confirmed the change in expression from the arrays 
for genes DUSP6 (dual specificity phosphatase 6), EGR1 (early growth 
response 1), GRLF1 (glucocorticoid receptor DNA binding factor), and 
SPHK2 (sphingosine kinase 2) in response to EGF and gefitinib at 12 
and 24 h. Calibration was to the corresponding control at the specific 
time points.
Figure 5 Real Time PCR Graphs for Chosen Genes in Ishikawa H 
cells. Data from qPCR confirmed the change in expression from the ar-
rays for genes DUSP6 (dual specificity phosphatase 6), EGR1 (early 
growth response 1), GRLF1 (glucocorticoid receptor DNA binding fac-
tor), and SPHK2 (sphingosine kinase 2) in response to EGF and gefitinib 
at 12 and 24 h. Calibration was to the corresponding control at the spe-
cific time points.Albitar et al. Molecular Cancer 2010, 9:166
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H cells express more isoform D compared to Hec50co
cells (Figure 4). It is unclear whether this finding relates
to the relative sensitivity of Ishikawa H cells to gefitinib
compared to more resistant Hec50co cells. However,
decreased serum levels of this same sEGFR isoform have
been reported in both ovarian [18,29] as well as endome-
trial cancer patients (preliminary findings, Leslie et al.,
unpublished results, and ASCO, 2009), and higher serum
sEGFR concentrations have been correlated with respon-
siveness to gefitinib in both lung and colon cancer
patients [30,31]. Since serum sEGFR arises from the iso-
form D transcript, there may be a link between these
observations, and further study of the function of this
sEGFR isoform in endometrial cancer is clearly war-
ranted. In this regard, serum sEGFR concentrations also
have been correlated with the female gonadotropin folli-
cle stimulating hormone, as well as with responsiveness
to treatment with the aromatase inhibitor letrozole in
breast cancer patients [32,33], suggesting a complex rela-
tionship between this novel serum biomarker and steroid
hormones such as estrogen and progesterone.
Gene expression was also evaluated in response to EGF
and gefitinib. The purpose of these studies was to explore
the genomic pathways activated or inhibited downstream
of EGFR in cells that are model of type I endometrial can-
cer and somewhat responsive to tyrosine kinase activa-
tion or inhibition versus those type II endometrial cancer
that are resistant. The most striking observation is the
apparent resistance of Hec50co cells to gefitinib at the
transcriptional level: the pattern of gene expression was
altered for fewer transcripts in response to gefitinib com-
pared to the more robust response observed in Ishikawa
H cells. These data are in agreement with our previous
work indicating that gefitinib had little effect on Hec50co
signaling pathways as assessed by phosphopeptide map-
ping [12] and analysis of cell cycle signaling events [13].
Together, these results combined with the genomic data
presented here confirm that poorly differentiated
Hec50co cells are resistant to gefitinib at multiple points
downstream of EGFR signaling. We previously have
linked gefitinib resistance in Hec50co cells with expres-
sion of the endogenous inhibitor of p53, MDM2, the
phospho-activation of which is not fully blocked by gefi-
tinib in this cell line [13]. Gene expression data from the
two cell lines was further analyzed using Venn diagrams
(Additional File 2, Figure S1). Alterations in the expres-
sion pattern of four differentially expressed genes were
confirmed by qPCR. Interestingly, EGFR blockade modu-
lates the downstream transcription activity of glucocorti-
coid receptor, predicting an anti-inflammatory and anti-
proliferative effect in Ishikawa H cells.
Another interesting gene product, the dual specificity
phosphastase (specific for ERK; DUSP6), was induced by
EGF at 12 and 24 h (2.839 and 2.867 fold, respectively)
and down-regulated by gefitinib treatment at 12 h and 24
h (0.288 and 0.381 fold, respectively) in Ishikawa H cells
(Additional File 1, Table S1). These changes were con-
firmed by qPCR (Figure 5). Such changes in DUSP6
e x p r e s s i o n  a p pe a r  t o  f o rm  pa rt  o f  a  n e g a t i v e  f eed ba c k
loop where EGF induces DUSP6, which then inhibits
ERK signaling downstream of EGFR.
Two other gene products, sphingosine kinase 2 (SphK2)
and EGR1, an early response transcription factor, were
also differentially regulated in these two cell lines. SphK2
message was down-regulated by gefitinib at 12 h (0.445
fold) and induced by gefitinib at 24 h (2.172 fold) in
Ishikawa H cells (Additional File 1, Table S1), indicating a
potential biphasic effect of gefitinib on apoptosis (inhib-
ited at 12 h, but induced at 24 h). EGR1, in contrast, is a
central target of EGFR signaling that is induced by recep-
tor activation and inhibited by tyrosine kinase blockade
(Figure 5). Further studies may be undertaken to deter-
mine whether inhibition of EGR1 expression by tyrosine
kinase inhibitors correlates with clinical response in
patients; here we identify EGR1 as a potential marker of
gefitinib response that warrants future investigation.
The findings from the Venn diagrams and Ingenuity™
networks, depicted in Additional Files 2, 3, 4, 5, 6, 7, 8, 9
and 10 (Figures S1-S9), show the genes regulated at 12
and 24 h by EGF or gefitinib in both Ishikawa H and
Hec50co cells in the context of their interacting path-
ways. Considering the expansive role of EGFR in cellular
functions, the genes consistently regulated in these cell
lines (Additional File 2, Figure S1) identifies a surprisingly
small core set of transcripts which may have utility as
markers of response to novel therapeutics targeting the
EGF pathway in patients with endometrial cancer.
The gene networks demonstrate that Ishikawa H cells
were robustly responsive to EGF at 12 h treatment,
including the induction of the central gene discussed
above, EGR1 (Additional File 3, Figure S2). EGR1 is func-
tionally linked to other genes upregulated by EGF treat-
ment at 12 h, including FOS, SMAD3, FOSL1, FGFR1,
MMP1, ETS1, SERPINE1, DUSP6, etc., which constitute
a growth-promoting pathway in response to EGF (Addi-
tional File 3, Figure S2); of this pathway, EGR1, SMAD3,
FOSL1, and MMP1 were also upregulated at 24 h of EGF
treatment (Additional File 4, Figure S3). Of interest, this
growth promoting pathway is linked to an immune mod-
ulatory transcriptional response, with IL-1β, IL-8,
TNFRF21, and TNFRSF10A all induced. It is, perhaps,
not surprising that proliferation and inflammation path-
ways are linked responses to EGF in endometrial carci-
noma-derived cells, as has been observed in other models
of cancer including hepatocellular carcinoma [34].
Consistent with this observation that an EGR1-contain-
ing pathway was upregulated by EGF treatment of
Ishikawa H cells, treatment with the EGFR inhibitor gefi-Albitar et al. Molecular Cancer 2010, 9:166
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tinib dampened EGR1 expression in Ishikawa H cells at
12 h (Additional File 5, Figure S4) and 24 h (Additional
File 6, Figure S5), along with concomitant downregula-
tion of expression of downstream genes such as FOSL1.
This core group of EGF-responsive genes was regulated
in the opposite manner by gefitinib. DUSP4 expression
was also inhibited by gefitinib, and may constitute
another marker gene of gefitinib response.
EGF/gefitinib-mediated transcriptional regulation in
the type II EC cell line Hec50co was generally blunted but
s h a r e d  s i m i l a r i t i e s  w i t h  t h o s e  o b s e r v e d  i n  I s h i k a w a  H
cells, as well as some surprising differences. EGF-medi-
ated EGR1 expression was upregulated at 12 h (Addi-
tional File 7, Figure S6), but not by 24 h (Additional File 8,
Figure S7) in Hec50co cells; gefitinib treatment failed to
inhibit EGR1 expression (Additional File 7, Figure S6 and
Additional File 8, Figure S7, respectively). Surprisingly,
EGF treatment caused a down-regulation of FGFR2
expression in Hec50co cells at both 12 h and 24 h.
At 12 h treatment (Additional File 9, Figure S8), gefi-
tinib induced the expression of HDAC5, a growth inhibi-
tory tumor suppressor and pro-apoptotic factor [35], in
Hec50co cells, while regulators of cell migration and
morphogenesis such as GIT1 and CALD1 were down-
regulated by gefitinib. Also at 12 h of gefitinib treatment,
APBA2 and RSP2, previously found to be highly
expressed in endometrial carcinomas [36] and prostate
cancer [37], respectively, were inhibited. However, by 24
h treatment (Additional File 10, Figure S9), Hec50co cells
demonstrated a transcriptional response that may be
compensatory to the anti-proliferative effects of gefitinib
in that some genes associated with malignant transforma-
tion and tumor progression were induced. For example,
ENC-1, often over-expressed in some types of leukemia
[38], KLF12, a transcription factor associated with pro-
gression of gastric cancer [39], and CDC42EP2, a small
Rho GTPase binding protein involved in hypoxia-
induced angiogenesis [40], were induced by gefitinib at 24
h treatment. The induction of SMAD5 by gefitinib is also
intriguing. SMAD5 has been characterized alternatively
as a tumor suppressor or growth promoter, depending on
cell context, so its specific function in response to gefi-
tinib will require further study to fully understand.
In summary, the Ingenuity™ networks suggest several
interesting findings. Ishikawa H cells are relatively
responsive at the level of transcription to the growth-pro-
moting effects of EGF and the growth inhibitory effect of
gefitinib, as exemplified by the induction or inhibition of
expression of a set of core genes including EGR1.
Hec50co cells, however, show less of a proliferative
response to EGF and an anti-proliferative response to
gefitinib, with possible compensatory signaling apparent
at 24 h treatment.
Conclusions
In summary , to the extent that Ishikawa H cells model
type I tumors, it is predicted that type I but not type II
endometrial cancers have the capacity to respond thera-
peutically to EGFR-targeted tyrosine kinase inhibitors.
Yet sequence analysis of hot spots within the tyrosine
kinase domain of the EGFR in both type I and type II-
derived cell lines revealed no mutations that might result
in such differential sensitivity. Hec50co cells do, however,
express lower levels of both sEGFR and EGFR, and such
differences are consistent with previous reports indicat-
ing that serum sEGFR levels may be a useful indicator of
responsiveness to gefitinib in other cancers, and also with
the observation that serum sEGFR is a useful predictor of
overall survival in endometrial cancer patients. In addi-
tion, our results suggest that type II endometrial tumors
may be more resistant to EGFR-targeted therapies, at
least in part, because they lack a genomic response that
includes the modulation of the gene products described
above in type I-derived endometrial cancer cells. If this
hypothesis is correct, the changes in gene expression pat-
terns observed here also may reveal potential biomarkers
that warrant further investigation as surrogate biomark-
ers of responsiveness or resistance to gefitinib.
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